摘要
目的制备磷酸川芎嗪缓释透皮贴剂并优化其处方。方法通过正交实验,筛选缓释透皮贴剂的处方组成。结果采用聚丙烯酸树脂EUDRAGITE100为控释骨架和压敏胶材料,1.0%氮酮作为渗透促进剂制备胶粘剂骨架型经皮给药系统,药物从胶粘剂骨架/药物储库(压敏胶层)中恒速释放,体外释放度表明,贴剂的释放符合零级方程。结论所研制的磷酸川芎嗪缓释透皮贴剂具有理想的释药特性。
Objective To optimize the formulation of Ligustrazine Phosphate Sustained-release patches. Methods The orthogonal design was used to screen the formulation of Ligustrazine Phosphate Sustained-release patches. Results The optimal combination of the formulation is EUDRAGIT E100 as the pressure sensitive adhesive, AZONE is acted as the enhancer with the content 1.0%. The study of in vitro release confirmed that Ligustrazine Phosphate were released by zero order equation from the patches. Conclusion The prepared Ligustrazine Phosphate Sustained-release patches had an ideal release trait.
出处
《药品评价》
CAS
2005年第4期292-294,共3页
Drug Evaluation
关键词
磷酸川芎嗪
缓释透皮贴剂
投药
皮肤
Ligustrazine Phosphate, Sustained-release patches, administration, cutaneous
